Creative Planning
GNMX

Creative Planning’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Creative Planning’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,000
Closed -$2K – 4953
2017
Q1 		$2K Sell
1,000
-9,000
-90% -$40.7K ﹤0.01% 4366
2016
Q4 		$52K Buy
10,000
+5,000
+100% +$26.3K ﹤0.01% 2367
2016
Q3 		$28K Buy
5,000
+2,000
+67% +$11.4K ﹤0.01% 2811
2016
Q2 		$17K Hold
3,000
– – ﹤0.01% 2925
2016
Q1 		$13K Hold
3,000
– – ﹤0.01% 3075
2015
Q4 		$18K Buy
3,000
+2,060
+219% +$14K ﹤0.01% 2932
2015
Q3 		$7K Buy
+940
New +$7.29K ﹤0.01% 3465
2015
Q2 		– Sell
-940
Closed -$8K – 3490
2015
Q1 		$8K Hold
940
– – ﹤0.01% 3352
2014
Q4 		$5K Buy
+940
New +$4.64K ﹤0.01% 3529

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Creative Planning's GNMX Position: Q2 2017 in Review

Creative Planning sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 1,000 shares — an estimated $2K sold.

Creative Planning first reported a position in GNMX in Q4 2014 and held it in 9 quarters. The position peaked at $52K in Q4 2016. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • Creative Planning reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • Creative Planning sold 1,000 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $2K.
  • Creative Planning first reported a position in Aevi Genomic Medicine Inc in Q4 2014 and held it in 9 quarters.
  • Creative Planning's Aevi Genomic Medicine Inc position peaked at $52K in Q4 2016.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Creative Planning's 13F filing for Q2 2017, filed 12 Jul 2017.